Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
about
Activation of rapid oestrogen signalling in aggressive human breast cancersTargeting Src family kinases in anti-cancer therapies: turning promise into triumphA conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivityBone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myelomaBone-targeted therapy in metastatic breast cancer - all well-established knowledge?Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers.S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer.An update on dual Src/Abl inhibitors.Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation studySafety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.Endothelial FAK as a therapeutic target in disease.Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBPδ expression and contributes to transformation of breast tumor cells.Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic PerspectivesBone-Targeted Agents for the Management of Breast Cancer Patients with Bone MetastasesActivation of abl family kinases in solid tumors.Clinical review: kinase inhibitors: adverse effects related to the endocrine system.Drug monographs: bosutinib and regorafenib.Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer.Novel targeted agents for the treatment of advanced breast cancer.Emerging targeted agents in metastatic breast cancer.Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.Pharmacological management of polycystic kidney disease.Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns.Novel investigational therapies for treating biliary tract carcinoma.Link synthetic lethality to drug sensitivity of cancer cells.SRC increases MYC mRNA expression in ER+ breast cancer via mRNA stabilization and inhibition of p53 function.Bone-Targeted Therapies in Cancer-Induced Bone Disease.A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.
P2860
Q24300885-AE47D20B-31ED-4158-9517-9575334DFCB3Q27025646-BA487CE6-1D52-445F-8305-45B75D2945CFQ27680722-F26968EC-B275-4228-9F01-960F4DBA9871Q28081996-F7B6DE38-1129-4B4E-96D4-EE70416E1EF4Q28087676-91724C83-0F58-4D44-90B8-DCEDDECAB9A5Q33403826-F24286D4-CCD9-4A60-BBDF-DC86FCE5A1F1Q33641010-08826C56-ECE7-427E-B52B-B1693CC6C083Q33961949-34C3A37D-2883-4742-B4D2-B27457D21C60Q34270677-76129AD6-182C-4D4B-AA5C-3084A8BAC204Q34480200-8654D978-2622-47FC-A565-8FB189B66184Q34658293-E2D8151E-9191-4D9C-BFD8-EECE8EC0CAA4Q35008618-F6E7F61F-0E68-40E2-B7AF-9227813740A5Q35597214-AD19704C-0C55-4231-A8E1-AA224112063CQ35665700-66214AFF-84F1-48C1-8CBD-EDD6868ACF97Q35667318-1DC2DCCA-5165-4D41-B05C-1A07AF02CEE3Q35750641-880EB31C-A528-4E81-9B48-E14B18C45E6EQ36443421-BE61228B-9585-4F60-9165-40B153BCF802Q36736494-D70BB255-DAAE-4E0E-AE6E-0E6282590293Q37340111-BC862324-7FD9-4A1E-881B-50C69760144AQ37720488-23101F28-6A7F-46FD-BE7A-4DB2FBB50A3EQ38008723-9D424F11-83F3-473E-8E83-83B1B1096890Q38086421-4A5BF723-86B1-4994-B0A8-3EF3A9C21C99Q38093654-14D24408-93D4-4572-9801-693CDF94CBBCQ38199755-FE1A898F-BEF4-4259-AA3E-BE8451894D4DQ38269966-7E4920D4-4EAB-481E-B348-F0CDFD268C67Q38799963-9EFAF918-CD9C-476E-BBEC-4752448F91CDQ47209937-A43B5CA0-E4DC-4E0D-B478-2CCD2DE9EF1EQ47230860-0821FA9B-1A9D-4AB1-9298-49A1AA79D3E9Q48110513-225752AE-D7DB-473F-9E82-20A5FBB11F24Q51337867-99E9AC50-06F5-4D74-84CF-715D55033FE4Q52633557-CD25BE90-2775-47F7-AC07-B3EA52E03BE3Q54478532-08FE790B-2898-41EE-B8AF-8AFAB61E22CB
P2860
Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
description
im Juni 2011 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в червні 2011
@uk
name
Phase II study of single-agent ...... r pretreated with chemotherapy
@en
Phase II study of single-agent ...... r pretreated with chemotherapy
@nl
type
label
Phase II study of single-agent ...... r pretreated with chemotherapy
@en
Phase II study of single-agent ...... r pretreated with chemotherapy
@nl
prefLabel
Phase II study of single-agent ...... r pretreated with chemotherapy
@en
Phase II study of single-agent ...... r pretreated with chemotherapy
@nl
P2093
P2860
P921
P356
P1433
P1476
Phase II study of single-agent ...... r pretreated with chemotherapy
@en
P2093
C. Zacharchuk
E. Chmielowska
K. Turnbull
M. Campone
N. Bardy-Bouxin
P. Fumoleau
P. N. Munster
R. J. Epstein
S. Brincat
P2860
P304
P356
10.1093/ANNONC/MDR261
P577
2011-06-23T00:00:00Z